• PDF / 167,351 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 35 Downloads / 174 Views

DOWNLOAD

REPORT

73-5503/20/0864-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 17 Oct 2020 No. 864

1

Recommend Documents

NICE recommends polatuzumab vedotin combination for DLBCL

185 46 163KB

Adding etonorgestrel implant in Indian health system cost effective

140 65 182KB

Cost-Effective

168 109 57MB

Atorvastatin cost effective in T2DM

163 57 182KB

Atomoxetine cost-effective in ADHD

158 88 139KB

Highly Cost-Effective Intervention

195 83 57MB

Brentuximab vedotin

131 96 166KB

Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with rel

106 47 800KB

Synflorix cost effective versus PCV13 in Taiwan

208 39 182KB

Trastuzumab cost effective in early breast cancer

115 43 122KB

Double CBT cost effective in acute leukaemia

157 46 115KB

Bevacizumab + capecitabine not cost effective in mCRC

162 48 111KB